From: How COVID-19 pandemic changed our management strategies for amyotrophic lateral sclerosis (ALS) patients: Egyptian study
Bulbar ALS
62.5%
Gastrostomy
3/8 (37.5%)
Botox injection
2/8 (25%)
NIV
8/8 (100%)